1. Medtech Insight
  2. >>Policy & Regulation

Year-End Spending Bill Sets FDA 2023 Budget At $6.6B

 
• By Elizabeth Orr

In addition to higher spending, the omnibus package now before the US Congress also addresses dual submissions, cybersecurity, pandemic preparedness, and more.  

US FDA with cloud dollars. photo illustration with Alamy and Shutterstock images
• Source: photo illustration/Alamy, Shutterstock images

The US Food and Drug Administration will see a major funding boost in the year-end omnibus spending bill, expected to pass Congress this week, with lawmakers allotting $6.6bn for the agency – up $226m from the 2022 budget. That includes $736.4m for the Center for Devices and Radiological Health.

The package doesn’t include much-anticipated diagnostics reform, which would have allowed the device center greater regulatory authority over lab-developed tests. But other FDA-related provisions in the package are drawing industry support, trade group AdvaMed says

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

Access To Library Tools Being Restored At US FDA

 
• By Sue Sutter and Derrick Gingery

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals and laid off librarians have not been reinstated.

FDA Announces Classifications On 8 Device Types

 
• By Elizabeth Orr

The US Food and Drug Administration has announced new classifications for eight device types that reached market via the de novo process, with most of the newly classified products in the diagnostics sector.

Medical Devices Not The Focus Of FDA’s Plans To Step Up Foreign Inspections, Expert Says

 
• By Brian Bossetta

The US FDA recently announced plans to carry out more unannounced inspections of foreign facilities. But those inspections will primarily target drug producers, with less attention and resources allocated to those making devices.